Hemogenyx Pharmaceuticals Plc
LSE: HEMO.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Vladislav Sandler
- Employees
- 16
- Headquarters
- London, United Kingdom
- IPO year
- 2015
- Market cap
- £44.3M
- Website
- https://www.hemogenyx.com
Loading HEMO…
Loading profile data…Frequently asked questions about HEMO
What does Hemogenyx Pharmaceuticals Plc (HEMO.L) do?
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refr...
Where does HEMO.L trade?
Hemogenyx Pharmaceuticals Plc (HEMO.L) trades on the London Stock Exchange.
What sector is HEMO.L in?
Hemogenyx Pharmaceuticals Plc (HEMO.L) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Hemogenyx Pharmaceuticals Plc?
Vladislav Sandler is the chief executive officer of Hemogenyx Pharmaceuticals Plc (HEMO.L).
Where is Hemogenyx Pharmaceuticals Plc headquartered?
Hemogenyx Pharmaceuticals Plc is headquartered in United Kingdom.
Does HEMO.L pay a dividend?
Hemogenyx Pharmaceuticals Plc (HEMO.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HEMO.L go public?
Hemogenyx Pharmaceuticals Plc (HEMO.L) completed its initial public offering in 2015.